Chemistry:Dapolsertib
From HandWiki
Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed by Ryvu Therapeutics SA.[1]
References
- ↑ "FLT3 inhibitors in acute myeloid leukemia". Journal of Hematology & Oncology 11 (1). December 2018. doi:10.1186/s13045-018-0675-4. PMID 30514344.
 |  |
